These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 32733560)

  • 1. Patterns and Prevalence of Germline
    Abdel-Razeq H; Abujamous L; Jadaan D
    J Oncol; 2020; 2020():8362179. PubMed ID: 32733560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patterns and Prevalence of
    Abdel-Razeq H; Tamimi F; Abujamous L; Edaily S; Abunasser M; Bater R; Salama O
    Cancer Manag Res; 2021; 13():4597-4604. PubMed ID: 34135636
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevalence and predictors of germline BRCA1 and BRCA2 mutations among young patients with breast cancer in Jordan.
    Abdel-Razeq H; Abujamous L; Abunasser M; Edaily S; Bater R
    Sci Rep; 2021 Jul; 11(1):14906. PubMed ID: 34290354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Germline BRCA1/BRCA2 mutations among high risk breast cancer patients in Jordan.
    Abdel-Razeq H; Al-Omari A; Zahran F; Arun B
    BMC Cancer; 2018 Feb; 18(1):152. PubMed ID: 29409476
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and clinical implications of germline mutations among Jordanian patients with ovarian cancer. The Jordanian exploratory cancer genetics (Jo-ECAG) ovarian study.
    Abdel-Razeq H; Al-Azzam K; Elemian S; Abu-Fares H; Abu Sheikha A; Bani Hani H; Bater R; Sharaf B; Heald B; Esplin ED; Nielsen SM; Alkyam M; Abujamous L; Al-Attary A
    Mol Genet Genomic Med; 2023 Apr; 11(4):e2125. PubMed ID: 36537080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Guideline-Based, Multi-Gene Panel Germline Genetic Testing for at-Risk Patients with Breast Cancer.
    Abdel-Razeq H; Abujamous L; Al-Azzam K; Abu-Fares H; Bani Hani H; Alkyam M; Sharaf B; Elemian S; Tamimi F; Abuhijla F; Edaily S; Salama O; Abdulelah H; Daoud R; Abubaker M; Al-Atary A
    Breast Cancer (Dove Med Press); 2023; 15():1-10. PubMed ID: 36660366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of pathogenic BRCA1/2 germline mutations among 802 women with unilateral triple-negative breast cancer without family cancer history.
    Engel C; Rhiem K; Hahnen E; Loibl S; Weber KE; Seiler S; Zachariae S; Hauke J; Wappenschmidt B; Waha A; Blümcke B; Kiechle M; Meindl A; Niederacher D; Bartram CR; Speiser D; Schlegelberger B; Arnold N; Wieacker P; Leinert E; Gehrig A; Briest S; Kast K; Riess O; Emons G; Weber BHF; Engel J; Schmutzler RK;
    BMC Cancer; 2018 Mar; 18(1):265. PubMed ID: 29514593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline
    Mehta A; Vasudevan S; Sharma SK; Kumar D; Panigrahi M; Suryavanshi M; Gupta G
    Cancer Manag Res; 2018; 10():6505-6516. PubMed ID: 30555256
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer: Secondary Analysis of the GeparSixto Randomized Clinical Trial.
    Hahnen E; Lederer B; Hauke J; Loibl S; Kröber S; Schneeweiss A; Denkert C; Fasching PA; Blohmer JU; Jackisch C; Paepke S; Gerber B; Kümmel S; Schem C; Neidhardt G; Huober J; Rhiem K; Costa S; Altmüller J; Hanusch C; Thiele H; Müller V; Nürnberg P; Karn T; Nekljudova V; Untch M; von Minckwitz G; Schmutzler RK
    JAMA Oncol; 2017 Oct; 3(10):1378-1385. PubMed ID: 28715532
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
    Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
    BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BRCA1 and BRCA2 genetic testing in Italian breast and/or ovarian cancer families: mutation spectrum and prevalence and analysis of mutation prediction models.
    Capalbo C; Ricevuto E; Vestri A; Ristori E; Sidoni T; Buffone O; Adamo B; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
    Ann Oncol; 2006 Jun; 17 Suppl 7():vii34-40. PubMed ID: 16760289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
    Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
    BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer.
    Risch HA; McLaughlin JR; Cole DE; Rosen B; Bradley L; Kwan E; Jack E; Vesprini DJ; Kuperstein G; Abrahamson JL; Fan I; Wong B; Narod SA
    Am J Hum Genet; 2001 Mar; 68(3):700-10. PubMed ID: 11179017
    [TBL] [Abstract][Full Text] [Related]  

  • 14. BRCA1 and BRCA2 mutation status and cancer family history of Danish women affected with multifocal or bilateral breast cancer at a young age.
    Bergthorsson JT; Ejlertsen B; Olsen JH; Borg A; Nielsen KV; Barkardottir RB; Klausen S; Mouridsen HT; Winther K; Fenger K; Niebuhr A; Harboe TL; Niebuhr E
    J Med Genet; 2001 Jun; 38(6):361-8. PubMed ID: 11389159
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
    Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
    BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Triple-negative breast cancer and PTEN (phosphatase and tensin homologue) loss are predictors of BRCA1 germline mutations in women with early-onset and familial breast cancer, but not in women with isolated late-onset breast cancer.
    Phuah SY; Looi LM; Hassan N; Rhodes A; Dean S; Taib NA; Yip CH; Teo SH
    Breast Cancer Res; 2012 Nov; 14(6):R142. PubMed ID: 23116406
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of BRCA1/2 mutational status among German and Austrian women with triple-negative breast cancer.
    Muendlein A; Rohde BH; Gasser K; Haid A; Rauch S; Kinz E; Drexel H; Hofmann W; Schindler V; Kapoor R; Decker T; Lang AH
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):2005-12. PubMed ID: 25971625
    [TBL] [Abstract][Full Text] [Related]  

  • 18. High frequency of pathogenic non-founder germline mutations in
    Maksimenko J; Irmejs A; Trofimovičs G; Bērziņa D; Skuja E; Purkalne G; Miklaševičs E; Gardovskis J
    Hered Cancer Clin Pract; 2018; 16():12. PubMed ID: 29928469
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reinterpretation of BRCA1 and BRCA2 variants of uncertain significance in patients with hereditary breast/ovarian cancer using the ACMG/AMP 2015 guidelines.
    So MK; Jeong TD; Lim W; Moon BI; Paik NS; Kim SC; Huh J
    Breast Cancer; 2019 Jul; 26(4):510-519. PubMed ID: 30725392
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Family history of breast and ovarian cancers and BRCA1 and BRCA2 mutations in a population-based series of early-onset breast cancer.
    Loman N; Johannsson O; Kristoffersson U; Olsson H; Borg A
    J Natl Cancer Inst; 2001 Aug; 93(16):1215-23. PubMed ID: 11504767
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.